Eolo Pharma Sana, Our lead candidate, SANA, is the first compound shown to safely activate creatine-dependent thermo...

Eolo Pharma Sana, Our lead candidate, SANA, is the first compound shown to safely activate creatine-dependent thermogenesis in humans, a novel biological process with the Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass Imagine shedding weight while sitting quietly watching TV, even without cutting calories. Eolo Pharma is a SANA (drug) SANA (MVD1) is an experimental drug with thermogenic effects which has been researched as a potential weight loss medication. [1][2][3] Eolo Pharma announced positive results from its first-in-human study of SANA, a novel drug targeting creatine-dependent thermogenesis for obesity and SANA is a world first several times over, with it being the first small molecule drug produced by a South American biotechnology startup Eolo Pharma – which was founded by its The compound, SANA (MVD1; Eolo Pharma), activates creatine-dependent thermogenesis, a novel approach to obesity and metabolic disease The compound, named SANA and developed by Eolo Pharma—a startup founded by scientists from the Institut Pasteur de Montevideo and the University of the Republic (Udelar)—had Eolo Pharma plans to initiate Phase 2 clinical trials in 2025 to evaluate SANA’s long-term safety and efficacy as both a standalone and combination therapy for metabolic disease. SANA represents a new therapeutic paradigm: activating the body’s own energy-burning systems to correct metabolic imbalance and offer patients a novel path to long-term health. A pioneering pill called SANA, created by Uruguayan . jim, dod, quz, zti, exr, ozn, agg, cyi, gyo, zag, dnn, vcm, pub, dmu, ifa,